The AIA at Ten-How Much Do the Pre-AIA Prior Art Rules Still Matter?
As the America Invents Act (AIA) turns 10, patent students across the country may ask: if the law is already a decade old, why am I spending so much time [...]
Branded Price Variation in the United States Drug Market, 2010 to 2019
Branded drug prices command considerable attention in the United States yet defining a drug’s price is not straightforward because they vary substantially across settings. We link branded drug prices across [...]
(When) Does Patent Protection Spur Cumulative Research Within Firms?
We estimate the effect of patent protection on follow-on investments in corporate scientific research. We exploit a new method for identifying an exogenous reduction in the protection a granted patent [...]
Bankrupt Innovative Firms
This paper studies how innovative firms manage their innovation portfolios after filing for Chapter 11 reorganization using three decades of data. We find that they sell off core (i.e., technologically [...]
Optimal Patent Policy for Pharmaceutical Industry
We show how characterizing optimal patent policy for the pharmaceutical industry only requires information about generic producers' responses to changes in the effective duration and scope of new drug patents. [...]
Crisis-Critical Intellectual Property: Findings From the COVID-19 Pandemic
A pandemic calls for large-scale action across national and international innovation systems in order to mobilize resources for developing and manufacturing crisis-critical products efficiently and in the huge quantities needed. [...]
Technological Improvement Rate Estimates for All Technologies: Use of Patent Data and an Extended Domain Description
In this work, we attempt to provide a comprehensive granular account of the pace of technological change. More specifically, we survey estimated yearly performance improvement rates for nearly all definable [...]
The Patents-Based Pharmaceutical Development Process: Rationale, Problems, and Potential Reforms
The pharmaceutical industry is facing substantial criticism from many directions, including financial barriers to access to drugs in both developed and developing countries, high profits, spending on advertising and marketing, [...]
Estimating The Cost Of Delayed Generic Drug Entry To Medicaid
Delays in market entry of generic drugs are common. This study sought to identify the prevalence of delayed entry, the reasons for the delays, and the delays’ effects on Medicaid [...]
Estimating The Cost Of Delayed Generic Drug Entry To Medicaid
Delays in market entry of generic drugs are common. This study sought to identify the prevalence of delayed entry, the reasons for the delays, and the delays’ effects on Medicaid [...]